An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ChromaDex Corp. (NASDAQ:CDXC) will report its first quarter 2024 financial results on May 8, 2024. The company specializes in NAD+ and healthy aging research. An investor conference call will be held to discuss the results and provide a business update. The call will take place at 4:30 p.m. ET on May 8, 2024.
ChromaDex Corp. (NASDAQ:CDXC) comunicherà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024. La società è specializzata nella ricerca sull'NAD+ e sull'invecchiamento sano. Si terrà una conferenza telefonica per gli investitori per discutere i risultati e fornire un aggiornamento sulle attività aziendali. La conferenza si svolgerà alle 16:30 ET dell'8 maggio 2024.
ChromaDex Corp. (NASDAQ:CDXC) presentará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. La empresa se especializa en la investigación del NAD+ y el envejecimiento saludable. Se llevará a cabo una conferencia telefónica con inversores para discutir los resultados y proporcionar una actualización sobre el negocio. La llamada se realizará a las 4:30 p.m. ET el 8 de mayo de 2024.
ChromaDex Corp. (NASDAQ:CDXC)는 2024년 5월 8일에 2024년 1분기 재무 결과를 보고할 예정입니다. 이 회사는 NAD+ 및 건강한 노화 연구를 전문으로 합니다. 투자자 컨퍼런스 콜이 결과를 논의하고 사업 업데이트를 제공하기 위해 개최될 예정입니다. 전화 회의는 2024년 5월 8일 오후 4시 30분 ET에 열립니다.
ChromaDex Corp. (NASDAQ:CDXC) annoncera ses résultats financiers pour le premier trimestre 2024 le 8 mai 2024. L'entreprise est spécialisée dans la recherche sur le NAD+ et le vieillissement sain. Une conférence téléphonique avec les investisseurs sera tenue pour discuter des résultats et pour fournir une mise à jour sur les activités de l'entreprise. L'appel aura lieu à 16h30 ET le 8 mai 2024.
ChromaDex Corp. (NASDAQ:CDXC) wird am 8. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen ist auf Forschung zu NAD+ und gesundem Altern spezialisiert. Es wird ein Investorentelefonat abgehalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben. Der Anruf findet um 16:30 Uhr ET am 8. Mai 2024 statt.
Positive
None.
Negative
None.
LOS ANGELES--(BUSINESS WIRE)--
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Investor Conference Call:
ChromaDex management will host an investor conference call to discuss the first quarter 2024 results and provide a general business update on Wednesday, May 8, at 4:30 p.m. ET. Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.
A replay of the conference call will be available from 7:30 p.m. ET on May 8, 2024, to 11:59 p.m. ET on May 15, 2024. The replay dial-in information is as follows:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.
*Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; and the risks and uncertainties associated with our business and financial condition in general, described in ChromaDex’s filings with the SEC, including without limitation, ChromaDex's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
When will ChromaDex report its first quarter 2024 financial results?
ChromaDex will report its first quarter 2024 financial results on Wednesday, May 8, 2024.
What is ChromaDex's ticker symbol?
ChromaDex's ticker symbol is CDXC (NASDAQ:CDXC).
When is the investor conference call to discuss the financial results scheduled?
The investor conference call to discuss the financial results is scheduled for Wednesday, May 8, 2024, at 4:30 p.m. ET.
Where can I find the webcast link for the ChromaDex First Quarter 2024 Earnings Conference Call?
The webcast link for the ChromaDex First Quarter 2024 Earnings Conference Call can be found on the investor relations section of the Company’s website at www.chromadex.com.
What is the toll-free replay number for the conference call?
The toll-free replay number for the conference call is 1-800-770-2030.
chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).
